abexinostat
Small moleculeexperimental
Abexinostat is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. As of 2013, it was in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well. — Wikipedia
Clinical trial activity
15 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
8
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2005 (NCT00473577)
Timeline
Indications
Studied for
- Astrocytoma · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 3
- Carcinoma, Transitional Cell · Phase 1
- Endometrial Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Glioblastoma · Phase 1
- Glioma · Phase 1
- Gliosarcoma · Phase 1
- Hamartoma · Phase 1
- Hematologic Neoplasms · Phase 1
- Hodgkin Disease · Phase 1/Phase 2
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Melanoma · Phase 1
- Multiple Myeloma · Phase 1
- Neoplasms · Phase 1
- Neoplasms by Site · Phase 1
- Oligodendroglioma · Phase 1
- Ovarian Neoplasms · Phase 1
- Sarcoma · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Ureteral Neoplasms · Phase 1
Mechanism of action
- Histone deacetylaseINHIBITOR
Histone deacetylase inhibitor
- Histone deacetylase 1 (HDAC1) ↗
- Histone deacetylase 3 (HDAC3) ↗
- Histone deacetylase 6 (HDAC6) ↗
- Histone deacetylase 2 (HDAC2) ↗
- Histone deacetylase 5 (HDAC5) ↗
- Histone deacetylase 7 (HDAC7) ↗
- Histone deacetylase 8 (HDAC8) ↗
- Histone deacetylase 11 (HDAC11) ↗
- Histone deacetylase 4 (HDAC4) ↗
- Histone deacetylase 9 (HDAC9) ↗
- Histone deacetylase 10 (HDAC10) ↗
- Histone deacetylase 8
- Histone deacetylase 10
- Histone deacetylase 2
- Histone deacetylase 3
- Histone deacetylase 4
- Histone deacetylase 6
- Histone deacetylase 9
- Histone deacetylase 11
- Histone deacetylase 5
- Histone deacetylase 7
- Histone deacetylase 1
- Histone deacetylase (HDAC1 and HDAC2)
- Histone deacetylase 1/3/5/8
- Histone deacetylase 1/2/3/6
- Histone deacetylase 1/2/3
- Histone deacetylase 1/8
- Histone deacetylase 1/6
- Class 1 histone deacetylase
- Histone deacetylase 6/3
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)Cc1c(C(=O)NCCOc2ccc(C(=O)NO)cc2)oc2ccccc12- Mol. weight
- 397.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAbexinostat ↗
- ChEMBLCHEMBL2103863 ↗
Also known as
- abexinostat
- abexinostat
- abexinostat
- abexinostat
- abexinostat
- cra024781
- cra 024781
- cra-024781
- cra-24781
- cra-24781
- pci24781
- pci 24781
- pci-24781
- pci-24781
- pci-24781
- pci-24781
- s-78454
- s-78454
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05698524 | Phase 1 | Jun 26, 2023 | University of Nebraska, Xynomic Pharmaceuticals, Inc. |
| NCT04498520 | Phase 1 | Mar 31, 2021 | Pfizer, University of California, San Francisco, Xynomic Pharmaceuticals, Inc. |
| NCT03934567 | Phase 2 | Dec 1, 2019 | Chinese Academy of Medical Sciences, Xynomic Pharmaceuticals, Inc. |
| NCT04024696 | Phase 1/Phase 2 (Phase 2) | Oct 15, 2019 | Chinese Academy of Medical Sciences, Xynomic Pharmaceuticals, Inc. |
| NCT03936153 | Phase 2 | Jul 30, 2019 | Chinese Academy of Medical Sciences, Xynomic Pharmaceuticals, Inc. |
| NCT03939182 | Phase 1/Phase 2 (Phase 2) | May 29, 2019 | Janssen Pharmaceutica NV, Memorial Sloan-Kettering Cancer Center, Xynomic Pharmaceuticals, Inc. |
| NCT03600441 | Phase 2 | Sep 1, 2018 | Memorial Sloan-Kettering Cancer Center, Xynomic Pharmaceuticals, Inc. |
| NCT03590054 | Phase 1 | Jul 19, 2018 | University of California, San Francisco, Xynomic Pharmaceuticals, Inc. |
| NCT03592472 | Phase 3 | Jul 17, 2018 | University of California, San Francisco, Xynomic Pharmaceuticals, Inc. |
| NCT01543763 | Phase 1 | May 1, 2012 | GlaxoSmithKline, Pharmacyclics, University of California, San Francisco |
| NCT01149668 | Phase 1 | Jun 1, 2010 | Pharmacyclics |
| NCT01027910 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2009 | Harvard University, Pharmacyclics |
| NCT00724984 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2008 | Pharmacyclics |
| NCT00562224 | Phase 1 | Nov 1, 2007 | Pharmacyclics, University of Chicago |
| NCT00473577 | Phase 1 | Aug 1, 2005 | Pharmacyclics, University of Chicago |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xynomic Pharmaceuticals, Inc. | For profit | 9 | 5 | 3 | 2018 |
| Pharmacyclics | For profit | 6 | 4 | 2 | 2005 |
| University of California, San Francisco | Academic/Hospital | 4 | 3 | 2 | 2012 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 3 | 0 | 1 | 2019 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 2 | 1 | 1 | 2018 |
| University of Chicago | Academic/Hospital | 2 | 0 | 1 | 2005 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2012 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2019 |
| Pfizer | For profit | 1 | 0 | 1 | 2021 |
| University of Nebraska | Academic/Hospital | 1 | 1 | 1 | 2023 |
11 organizations
Page 1 / 1